NASDAQ:NEO - NeoGenomics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.83
  • Forecasted Upside: 21.79 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$43.38
▼ -0.22 (-0.50%)

This chart shows the closing price for NEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeoGenomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEO

Analyst Price Target is $52.83
▲ +21.79% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $52.83, with a high forecast of $65.00 and a low forecast of $14.50. The average price target represents a 21.79% upside from the last price of $43.38.

This chart shows the closing price for NEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in NeoGenomics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$53.00High
8/26/2021BenchmarkBoost Price TargetBuy$46.00 ➝ $50.00High
8/9/2021Morgan StanleyLower Price TargetOverweight$64.00 ➝ $58.00High
8/9/2021Needham & Company LLCReiterated RatingBuy$55.00Medium
7/13/2021Needham & Company LLCInitiated CoverageBuy$55.00Low
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$55.00Low
4/16/2021Needham & Company LLCReiterated RatingBuy$65.00Medium
3/3/2021Raymond JamesReiterated RatingOutperform ➝ Market PerformN/A
2/25/2021Craig HallumBoost Price TargetIn-Line ➝ Buy$50.00 ➝ $65.00Low
2/25/2021Morgan StanleyBoost Price TargetOverweight$46.00 ➝ $64.00High
2/25/2021Needham & Company LLCInitiated CoverageBuy$65.00High
2/25/2021Needham & Company LLCReiterated RatingBuy$65.00High
2/25/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
1/27/2021TruistInitiated CoverageBuy$65.00Low
1/8/2021SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $60.00High
12/11/2020BTIG ResearchInitiated CoverageBuyLow
11/20/2020SVB LeerinkBoost Price TargetOutperform$47.00 ➝ $50.00High
10/28/2020Craig HallumBoost Price TargetBuy$42.00 ➝ $50.00Low
10/28/2020Raymond JamesBoost Price TargetOutperform$40.00 ➝ $48.00Medium
10/28/2020BenchmarkBoost Price TargetBuy$40.00 ➝ $48.00High
10/28/2020Needham & Company LLCBoost Price TargetAverage ➝ Buy$39.00 ➝ $46.00High
10/28/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $47.00High
10/26/2020CIBCUpgradeOutperformer$10.50 ➝ $14.50Medium
9/9/2020Morgan StanleyInitiated CoverageOverweight$46.00High
8/28/2020GuggenheimInitiated CoverageBuy$46.00Medium
7/29/2020Craig HallumBoost Price TargetIn-Line ➝ Buy$36.00 ➝ $42.00Low
7/29/2020SVB LeerinkBoost Price TargetOutperform$35.00 ➝ $45.00Low
7/29/2020Raymond JamesBoost Price TargetOutperform$32.00 ➝ $40.00Medium
7/29/2020BenchmarkBoost Price TargetBuy$35.00 ➝ $40.00High
7/29/2020Needham & Company LLCBoost Price TargetBuy$33.00 ➝ $39.00High
6/25/2020Bank of AmericaInitiated CoverageBuy$34.00High
5/27/2020Needham & Company LLCReiterated RatingBuy$33.00High
5/15/2020CIBCDowngradeNeutral$11.00 ➝ $9.00Low
4/29/2020SVB LeerinkReiterated RatingBuy$33.00 ➝ $35.00High
4/29/2020Needham & Company LLCReiterated RatingBuy$33.00High
4/21/2020StephensInitiated CoverageOverweight$33.00High
3/17/2020Needham & Company LLCBoost Price TargetBuy$32.00 ➝ $33.00High
3/2/2020Craig HallumInitiated CoverageBuy$38.00Low
3/2/2020Raymond JamesBoost Price TargetOutperform$28.00 ➝ $32.00High
2/28/2020BenchmarkBoost Price TargetAccumulate ➝ Buy$27.00 ➝ $30.00Medium
2/28/2020Needham & Company LLCBoost Price TargetBuy$29.00 ➝ $32.00Medium
2/28/2020First AnalysisUpgradeOutperform ➝ Strong-Buy$35.00High
1/23/2020First AnalysisDowngradeStrong-Buy ➝ Outperform$29.00 ➝ $35.00Low
1/3/2020Needham & Company LLCInitiated CoverageBuy$14.00Low
10/30/2019Needham & Company LLCBoost Price TargetBuy$27.00 ➝ $29.00High
10/29/2019William BlairReiterated RatingOutperformLow
7/31/2019SVB LeerinkSet Price TargetBuy$30.00Medium
7/31/2019Needham & Company LLCSet Price TargetBuy$27.00Medium
7/31/2019BenchmarkSet Price TargetBuy$27.00Medium
7/31/2019Raymond JamesBoost Price TargetOutperform$23.00 ➝ $27.00Medium
5/1/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $24.00High
3/29/2019Needham & Company LLCBoost Price TargetBuy ➝ Buy$19.00 ➝ $22.00High
3/12/2019CIBCUpgradeNeutral ➝ Outperform$18.00 ➝ $15.00Medium
1/3/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$14.00High
12/4/2018Raymond JamesReiterated RatingBuy$24.00High
11/16/2018ScotiabankReiterated RatingBuy ➝ Average$24.00Low
11/1/2018BenchmarkSet Price TargetBuy$22.00Medium
10/31/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$16.00 ➝ $21.00Low
10/31/2018Craig HallumBoost Price TargetBuy$17.00 ➝ $22.00Medium
9/18/2018First AnalysisSet Price TargetBuy$16.00High
8/21/2018SVB LeerinkInitiated CoverageOutperform$18.00High
6/26/2018StephensReiterated RatingBuy$15.00Medium
6/21/2018BTIG ResearchReiterated RatingBuy$15.00High
5/2/2018First AnalysisDowngradeOverweight ➝ Equal Weight$11.00Medium
4/16/2018BTIG ResearchUpgradeNeutral ➝ OutperformHigh
3/13/2018Canaccord GenuityBoost Price Target$23.00 ➝ $24.00Medium
3/13/2018Royal Bank of CanadaBoost Price TargetOutperform$23.00 ➝ $24.00Medium
3/13/2018ScotiabankBoost Price TargetOutperform$22.00 ➝ $23.00Medium
1/3/2018Royal Bank of CanadaSet Price TargetOutperform$23.00Low
1/3/2018ScotiabankSet Price TargetOutperform$22.00Low
1/3/2018CIBCSet Price TargetNeutral$19.00Low
10/26/2017Janney Montgomery ScottReiterated RatingBuyN/A
9/11/2017BTIG ResearchDowngradeBuy ➝ NeutralHigh
8/24/2017GabelliInitiated CoverageBuy$9.00High
5/28/2017BTIG ResearchReiterated RatingBuy$11.00Low
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/A
4/26/2017Cantor FitzgeraldReiterated RatingBuy$11.00High
3/22/2017Cantor FitzgeraldReiterated RatingOverweight$11.00Low
3/13/2017Cantor FitzgeraldSet Price TargetBuy$11.00Low
2/22/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/A
12/25/2016Cantor FitzgeraldSet Price TargetBuy$11.00N/A
12/15/2016Cantor FitzgeraldInitiated CoverageOverweight$11.00N/A
11/16/2016Axiom SecuritiesReiterated RatingHold ➝ SellN/A
10/27/2016BTIG ResearchUpgradeNeutral ➝ Buy$10.00N/A
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/19/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/18/2021
  • 3 very positive mentions
  • 25 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
10/18/2021

Current Sentiment

  • 3 very positive mentions
  • 25 positive mentions
  • 4 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

NeoGenomics logo
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Read More

Today's Range

Now: $43.38
Low: $43.22
High: $44.49

50 Day Range

MA: $46.38
Low: $40.87
High: $52.52

52 Week Range

Now: $43.38
Low: $36.00
High: $61.57

Volume

934,200 shs

Average Volume

875,403 shs

Market Capitalization

$5.33 billion

P/E Ratio

76.11

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of NeoGenomics?

The following Wall Street sell-side analysts have issued research reports on NeoGenomics in the last year: Benchmark Co., BTIG Research, CIBC, Craig Hallum, Morgan Stanley, Needham & Company LLC, Raymond James, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist, and Zacks Investment Research.
View the latest analyst ratings for NEO.

What is the current price target for NeoGenomics?

9 Wall Street analysts have set twelve-month price targets for NeoGenomics in the last year. Their average twelve-month price target is $52.83, suggesting a possible upside of 21.8%. Craig Hallum has the highest price target set, predicting NEO will reach $65.00 in the next twelve months. CIBC has the lowest price target set, forecasting a price of $14.50 for NeoGenomics in the next year.
View the latest price targets for NEO.

What is the current consensus analyst rating for NeoGenomics?

NeoGenomics currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NEO will outperform the market and that investors should add to their positions of NeoGenomics.
View the latest ratings for NEO.

How do I contact NeoGenomics' investor relations team?

NeoGenomics' physical mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company's listed phone number is (239) 768-0600 and its investor relations email address is [email protected] The official website for NeoGenomics is www.neogenomics.com.